Create an Account
  1. Home
  2. Specialty
  3. Retina

From Trials to Treatments: Inflammatory Events Following Intravitreal Injection: Infectious Endophthalmitis vs Sterile Inflammatory Responses - Part 3

From Trials to Treatments Inflammatory Events Following Intravitreal Injection Infectious Endophthalmitis vs Sterile Inflamma
Media formats available:
Details
Presenters

  • Overview

    This educational activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to: 
    • Recognize the importance of early diagnosis and treatment of age-related macular degeneration and diabetic macular edema
    • Assess the response of anti-vascular endothelial growth factor intravitreal injections, and define “suboptimal responders”
    • Understand the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and RVO
    • Discuss the outcomes of pivotal studies in AMD, DME, and RVO and how study results may differ from “real-world” dosing methods
    • Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe
    • Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations

  • Accreditation

    Accreditation Statement Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Faculty and Disclosures

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

    Rishi P. Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alcon; Allergan  Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc. Charles Wykoff, MD, PhD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant:  Alimera Sciences, Inc.; Allergan, plc; Alnylam; Bayer Pharmaceuticals; Clearside Biomedical, Inc.; CORCEPT; DORC International; EyePoint/pSivida; Genentech, Inc.; Notal Vision; Novartia; ONL Therapeutics; Regeneron Pharmaceuticals, Inc; Roche; and Santen Pharmaceuticals. Speaker’s Bureau:  Allergan, plc. and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Adverum; Aerpio; Alcon; Aldeyra; Allegro Ophthalmics; Allergan, Inc.; Apellis Pharmaceuticals; Astellas; Aura; Boehringer Ingelheim; Chiltern; Clearside Biomedical, Inc.; EyePoint/pSivida; Genentech, Inc; Heidleberg; Iconic Therapeutics; John’s Hopkins University; NEI; Novartis; OHR; Opthotech Corporation; Regeneron Pharmaceuticals, Inc; Regenxbio; Roche; Santen Pharmaceutical Co., Ltd.; SciFlour; Taiwan Liposome Company; and Tyrogenex. EDITORIAL SUPPORT DISCLOSURES Erin K. Fletcher, MIT, director of compliance and education, Evolve, has no financial relationships with commercial interests. Susan Gallagher-Pecha, director of client services and project management, Evolve, has no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve  or Regeneron Pharmaceuticals, Inc. OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free